title: [Assessment of hand-foot syndrome in cancer outpatients undergoing chemotherapy].
abstract: Capecitabine, an oral prodrug of 5 -fluorouracil, is a promising treatment for colorectal, breast, and gastric cancers, but often causes hand-foot syndrome(HFS), which is the most common dose-limiting toxicity. The aim of this study was to evaluate of the efficacy of the pharmacist in providing support at ambulatory therapy centers, especially for HFS. The HFS is a higher-incidence adverse event that may develop during chemotherapy with capecitabine. Once developed, the symptoms significantly impair quality of life(QOL), leading to a reduction in the dosage or discontinuation of the treatment. Patient symptoms may therefore increase in severity. This study was performed to analyze the treatment adherence and adverse events resulting from capecitabine therapy provided by pharmacists to cancer outpatients. All patients were prescribed vitamin B6(pyridoxine), which can help to reduce or prevent HFS. A lesser or milder extent of HFS was detected in patients who had used a moisturizer at the same time as the introduction of capecitabine therapy. Adherence to this approach will benefit the patients' selfcare in maintaining moisture retention, which is an important countermeasure for HFS. Additionally, early introduction of effective countermeasures for skin care, dose reduction, and rest periods is important for HFS management; in addition, team care support is dispensable. Our support system may be useful for management strategies for HFS. We suggest that improved quality of lif e is needed in cancer outpatients being treated with chemotherapy.
authors.affiliation: Dept. of Pharmacy, Saiseikai Shigaken Hospital.
authors.forename: Keiko
authors.initials: K
authors.lastname: Takeda
authors.forename: Tadashi
authors.initials: T
authors.lastname: Shigematsu
authors.forename: Masahiro
authors.initials: M
authors.lastname: Shirai
authors.forename: Kouhei
authors.initials: K
authors.lastname: Yamagiwa
authors.forename: Keiko
authors.initials: K
authors.lastname: Amamori
authors.forename: Kazumi
authors.initials: K
authors.lastname: Sunda
authors.forename: Toshimi
authors.initials: T
authors.lastname: Yamanda
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D000069287:Capecitabine; D003110:Colonic Neoplasms / Q000188:drug therapy; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives*; D060831:Hand-Foot Syndrome / Q000175:diagnosis*; D006801:Humans; D010045:Outpatients; D011788:Quality of Life
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil